Gold Standard Diagnostics

Gold Standard Diagnostics is a company that provides advanced diagnostic solutions for laboratory applications, specializing in assay kits for various diseases, improving clinical testing efficiency and accuracy. Gold Standard Diagnostics (GSD) specializes in diagnostic solutions for laboratory applications, including assay kits for medical testing. The company is headquartered in Davis, US. GSD raised USD 1 million in financing from unspecified investors on January 14, 2013.

The company does not have reported subsidiaries or significant business strategy pivots. The founder's history is not provided. Gold Standard Diagnostics, a Eurofins Technologies company, specializes in providing comprehensive diagnostic solutions tailored for laboratory applications. The company's core product offerings include a range of assay kits designed for various diagnostic purposes, such as the B.

burgdorferi VlsE-OspC IgG/IgM Assay, which aids in early detection of Lyme disease. These innovative instruments enhance laboratory quality and consistency, allowing end users, including clinical laboratories and healthcare facilities, to streamline their diagnostic processes. GSD’s products are marketed globally, with a particular focus on the large U. S.

clinical laboratory market, ensuring that their solutions meet diverse healthcare needs across different geographical regions. Gold Standard Diagnostics generates revenue through the sale of its diagnostic products to clinical laboratories worldwide. The company's transaction structure typically involves direct sales to B2B clients, including hospitals and diagnostic laboratories, which utilize GSD’s products for patient testing. The sales process may include bulk purchases of assay kits and laboratory automation solutions, enhancing the efficiency and cost-effectiveness of their clients' operations.

GSD’s flagship products, such as the recently FDA-cleared B. burgdorferi IgG/IgM VlsE-OspC EIA test, provide targeted solutions that meet specific diagnostic requirements in the laboratory setting. The firm’s revenue model is supported by a commitment to deliver high-quality, reliable diagnostic tools that address critical healthcare challenges. Gold Standard Diagnostics is developing new products and plans to expand its market presence.

The company aims to introduce additional diagnostic assays to enhance its product portfolio. The recent funding of USD 1 million raised in January 2013 will be utilized to support product development and market expansion initiatives. GSD is targeting growth in international markets, particularly focusing on increasing its footprint within the large U. S.

clinical laboratory market.